1.Pharmacognostic evaluation of Lens culinaris Medikus seeds
Vohra Kripi ; Gupta Kumar Vivek
Asian Pacific Journal of Tropical Biomedicine 2012;(z3):1221-1226
Objective: To present a detailed pharmacognostic study of the Lens culinaris Medikus (Fabaceae) seeds, a food grain used as Dhal in India. Methods: The macroscopy, microscopy, fluorescence analysis of powdered drug, physicochemical analysis, preliminary testing and other WHO recommended methods for standardization were investigated. Results: Seeds are greyish brown in colour. Treatment of powdered drug with various chemical reagents showed the presence of proteins, cellulose, lignins and fixed oils. Microscopy of seeds revealed the presence of starch grains in seed. The colour of seed coat changed from brown to greenish grey in day light and brown to black at 254nm when treated with acetic acid. Total ash value of the seeds was found to be 1.86% w/w whereas foreign organic matter was found to be nil. Qualitative phytochemical analysis revealed the presence of tannins and flavonoids in acetone extract. Conclusions: The present study on pharmacognostic profile of Lens culinaris Medikus seeds provides an important tool in identification and authentication of this plant to researchers in future.
2.Early Transneuronal Degeneration in Dyke-Davidoff-Masson Syndrome.
Anu GUPTA ; Manoj Kumar GOYAL ; Parampreet SINGH ; Vivek LAL
Journal of Clinical Neurology 2016;12(1):117-118
No abstract available.
3.Impact of scaling and root planing on C-reactive protein levels in gingival crevicular fluid and serum in chronic periodontitis patients with or without diabetes mellitus.
Mahendra MOHAN ; Rajesh JHINGRAN ; Vivek Kumar BAINS ; Vivek GUPTA ; Rohit MADAN ; Iram RIZVI ; Kanchan MANI
Journal of Periodontal & Implant Science 2014;44(4):158-168
PURPOSE: The present study was conducted to evaluate the impact of scaling and root planing (SRP) on the C-reactive protein (CRP) levels of gingival crevicular fluid (GCF) and serum in chronic periodontitis patients with type 2 diabetes mellitus (T2DM-CP) or without type 2 diabetes mellitus (NDM-CP). METHODS: Forty-eight human participants were divided into two groups: an experimental (T2DM-CP) group (group I, n=24) comprising chronic periodontitis patients with random blood sugar > or =200 mg/dL and type 2 diabetes mellitus, and control (NDM-CP) group (group II, n=24) of those with chronic periodontitis and random blood sugar <200 without T2DM for the study. All subjects underwent nonsurgical periodontal therapy (NSPT) including complete SRP and subgingival debridement. Periodontal health parameters, plaque index (PI), gingival index (GI), probing pocket depth (PPD), clinical attachment level (CAL), GCF volume (GCF vol), GCF-CRP, random blood glucose (RBS), glycated hemoglobin, and systemic inflammatory markers, serum CRP, total leukocyte count (TLC), neutrophil count (Neutr) and lymphocyte count (Lymph), were evaluated at baseline, 1 month, and 3 months after SRP. RESULTS: NSPT resulted in statistically significant improvement in periodontal health parameters (PI, GI, PPD, CAL, GCF vol), CRP levels in serum as well as GCF of both groups I and II. The mean improvement in periodontal health parameters (PI, GI, PPD, CAL, GCF vol), CRP levels in serum and GCF was greater in group I than group II after NSPT. There was nonsignificant increase in GCF-CRP, TLC, Lymph, and RBS, and a significant increase in Neutr and Serum CRP in group II at 1 month. The Serum CRP level of 20 out of 24 group II patients had also increased at 1 month. CONCLUSIONS: The CRP levels in both GCF and serum were higher in T2DM-CP patients than in NDM-CP patients. Although there was a significant improvement in both the groups, greater improvement was observed in both GCF and serum samples of T2DM-CP patients.
Biomarkers
;
Blood Glucose
;
C-Reactive Protein*
;
Chronic Periodontitis*
;
Debridement
;
Diabetes Mellitus*
;
Diabetes Mellitus, Type 2
;
Gingival Crevicular Fluid*
;
Hemoglobin A, Glycosylated
;
Humans
;
Leukocyte Count
;
Lymphocyte Count
;
Neutrophils
;
Periodontal Index
;
Root Planing*
4.Diagnostic performance of microRNA-34a, let-7f and microRNA-31 in epithelial ovarian cancer prediction
Vivek KUMAR ; Sameer GUPTA ; Kachnar VARMA ; Amrita CHAURASIA ; Manisha SACHAN
Journal of Gynecologic Oncology 2022;33(4):e49-
Objective:
To correlate the genome-wide methylation signature of microRNA genes with dysregulated expression of selected candidate microRNA in tissue and serum samples of epithelial ovarian cancer (EOC) and control using quantitative reverse transcription polymerase chain reaction (qRT-PCR), and evaluation of EOC predictive value of candidate microRNA at an early stage.
Methods:
We performed Methylated DNA Immunoprecipitation coupled with NGS (MeDIP-NGS) sequencing of 6 EOC and 2 normal tissue samples of the ovary. Expression of selected microRNA from tissue (EOC=85, normal=30) and serum (EOC=50, normal=15) samples was evaluated using qRT-PCR. We conducted bioinformatics analysis to identify the candidate miRNA’s potential target and functional role.
Results:
MeDIP-NGS sequencing revealed hypermethylation of several microRNAs gene promoters. Three candidate microRNAs were selected (microRNA-34a, let-7f, and microRNA-31) from MeDIP-NGS data analysis based on log2FC and P-value. The relative expression level of microRNA-34a, let-7f, and microRNA-31 was found to be significantly reduced in early-stage EOC tissues and serum samples (p<0.0001). The receiver operating characteristic analysis of microRNA-34a, let-7f and miR-31 showed improved diagnostic value with area under curve(AUC) of 92.0 (p<0.0001), 87.9 (p<0.0001), and 85.6 (p<0.0001) and AUC of 82.7 (p<0.0001), 82.0 (p<0.0001), and 81.0 (p<0.0001) in stage III-IV and stage I-II EOC serum samples respectively. The integrated diagnostic performance of microRNA panel (microRNA-34a+let-7f+microRNA-31) in late-stage and early-stage serum samples was 95.5 and 96.9 respectively.
Conclusion
Our data correlated hypermethylation-associated downregulation of microRNA in EOC. In addition, a combined microRNA panel from serum could predict the risk of EOC with greater AUC, sensitivity, and specificity.
5.Small Cell Type Undifferentiated Carcinoma of Gall Bladder with Pas Positive Hyaline Globule Masquerading as Liver Mass: A Case Report and Literature Review
Raman K. GUPTA ; Vishal K. CHORASIYA ; Vivek VIJ ; Manav WADHAWAN ; Ajay KUMAR ; Nalini BANSAL
The Korean Journal of Gastroenterology 2023;81(1):40-45
An undifferentiated carcinoma (UC) of the gall bladder behaves aggressively and has a grave prognosis. Small cell type undifferentiated carcinoma of the gall bladder is a rare variant. This paper reports a case of UC of gall bladder with PAS-positive diastase-resistant eosinophilic hyaline globules present as liver mass (on imaging) in a male patient. The microscopic findings of the liver and gall bladder after a right tri-segmentectomy showed an un-differentiated malignant neoplasm composed of cells with round to oval nuclei, prominent nucleoli, and scanty neoplasm. No definite cell pattern was identified with these neoplastic cells. A section from the gall bladder revealed a tumor arising from the lining epithelium and infiltrating through the muscularis. This tumor was infiltrating the adherent liver tissue directly and forming a mass of undifferentiated malignant cells. The focal area within the tumor mass showed the presence of PAS-positive, diastase-resistant, eosinophilic hyaline globules within the neoplastic cells. The immunohistochemistry test was diffusely positive for perinuclear anti-neutrophil cytoplasmic antibodies and negative for chromogranin, vimentin, Desmin, alpha-fetoprotein, leukocyte common antigen, CD34, and bcl2. When the clinical and radiological data are inconclusive, careful analysis of the histological and immunophenotypic features is needed to make the final diagnosis of UC of the gall bladder. The biological behavior and prognosis of this tumor remain unclear because of its rarity. Further studies will be needed to understand the characteristics of this deadly tumor and to establish an effective therapy for it.
6.Addition of 2 mg dexamethasone to improve the anesthetic efficacy of 2% lidocaine with 1:80,000 epinephrine administered for inferior alveolar nerve block to patients with symptomatic irreversible pulpitis in the mandibular molars: a randomized double-blind clinical trial
Vivek AGGARWAL ; Tanveer AHMAD ; Mamta SINGLA ; Alpa GUPTA ; Masoud SAATCHI ; Mukesh HASIJA ; Babita MEENA ; Umesh KUMAR
Journal of Dental Anesthesia and Pain Medicine 2022;22(4):305-314
Methods:
In a double-blinded setup, 124 patients randomly received either of the following injections: 2% lidocaine with 1:80,000 epinephrine, 2% lidocaine with 1:80,000 epinephrine mixed with 2 mg dexamethasone, or plain 2% lidocaine mixed with 2 mg dexamethasone, which were injected as a primary IANB. Ten minutes after injection, patients with profound lip numbness underwent electric and thermal pulp sensibility tests. Patients who responded positively to the tests were categorized as “failed” anesthesia and received supplemental anesthesia. The remaining patients underwent endodontic treatment using a rubber dam. Anesthetic success was defined as “no pain or faint/weak/mild pain” during endodontic access preparation and instrumentation (HP visual analog scale score < 55 mm). The effect of the anesthetic solutions on the maximum change in heart rate was also evaluated. The Pearson chi-square test at 5% and 1% significance was used to analyze anesthetic success rates.
Results:
The 2% lidocaine with 1:80,000 epinephrine, 2% lidocaine with 1:80,000 epinephrine mixed with 2 mg dexamethasone, and plain 2% lidocaine mixed with 2 mg dexamethasone groups had anesthetic success rates of 34%, 59%, and 29%, respectively. The addition of dexamethasone resulted in significantly better results (P < 0.001, χ 2 = 9.07, df = 2).
Conclusions
The addition of dexamethasone to 2% lidocaine with epinephrine, administered as an IANB, can improve the anesthetic success rates during the endodontic management of symptomatic mandibular molars with irreversible pulpitis.
7.Addendum: Addition of 2 mg dexamethasone to improve the anesthetic efficacy of 2% lidocaine with 1:80,000 epinephrine administered for inferior alveolar nerve block to patients with symptomatic irreversible pulpitis in the mandibular molars: a randomized double-blind clinical trial
Vivek AGGARWAL ; Tanveer AHMAD ; Mamta SINGLA ; Alpa GUPTA ; Masoud SAATCHI ; Mukesh HASIJA ; Babita MEENA ; Umesh KUMAR
Journal of Dental Anesthesia and Pain Medicine 2023;23(1):54-
8.Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of ¹⁸F-Fluorocholine PET/CT in MEN1 Syndrome
Saurabh ARORA ; Nishikant Avinash DAMLE ; Averilicia PASSAH ; Madhav Prasad YADAV ; Sanjana BALLAL ; Vivek AGGARWAL ; Yashdeep GUPTA ; Praveen KUMAR ; Madhavi TRIPATHI ; Chandrasekhar BAL
Nuclear Medicine and Molecular Imaging 2018;52(3):238-242
Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by combined occurrence of tumors of endocrine glands including the parathyroid, the pancreatic islet cells, and the anterior pituitary gland. Parathyroid involvement is the most common manifestation and usually the first clinical involvement inMEN1 syndrome, followed by gastroentero-pancreatic neuroendocrine tumors (NETs). Here we present a case where the patient initially presented with metastatic gastric NET and a single parathyroid adenoma was detected incidentally on ⁶⁸Ga-DOTANOC PET/CT done as part of post ¹⁷⁷Lu-DOTATATE therapy (PRRT) follow-up. Further ¹⁸F-fluorocholine PET/CT showed four adenomas for which the patient subsequently underwent subtotal parathyroidectomy.
Adenoma
;
Endocrine Glands
;
Follow-Up Studies
;
Gastrinoma
;
Humans
;
Hyperparathyroidism
;
Islets of Langerhans
;
Multiple Endocrine Neoplasia Type 1
;
Neuroendocrine Tumors
;
Parathyroid Neoplasms
;
Parathyroidectomy
;
Pituitary Gland, Anterior
;
Positron-Emission Tomography and Computed Tomography
;
Receptors, Somatostatin
;
Somatostatin
9.Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of ¹â¸F-Fluorocholine PET/CT in MEN1 Syndrome
Saurabh ARORA ; Nishikant Avinash DAMLE ; Averilicia PASSAH ; Madhav Prasad YADAV ; Sanjana BALLAL ; Vivek AGGARWAL ; Yashdeep GUPTA ; Praveen KUMAR ; Madhavi TRIPATHI ; Chandrasekhar BAL
Nuclear Medicine and Molecular Imaging 2018;52(3):238-242
Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by combined occurrence of tumors of endocrine glands including the parathyroid, the pancreatic islet cells, and the anterior pituitary gland. Parathyroid involvement is the most common manifestation and usually the first clinical involvement inMEN1 syndrome, followed by gastroentero-pancreatic neuroendocrine tumors (NETs). Here we present a case where the patient initially presented with metastatic gastric NET and a single parathyroid adenoma was detected incidentally on â¶â¸Ga-DOTANOC PET/CT done as part of post ¹â·â·Lu-DOTATATE therapy (PRRT) follow-up. Further ¹â¸F-fluorocholine PET/CT showed four adenomas for which the patient subsequently underwent subtotal parathyroidectomy.